Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of nonmelanoma skin cancer

Nonmelanoma skin cancers (NMSCs) are some of the most commonly diagnosed malignancies. In general, early-stage NMSCs have favorable outcomes; however, a small subset of patients develop resistant, advanced, or metastatic disease, or aggressive subtypes that are more challenging to treat successfully. Recently, immune checkpoint inhibitors (ICIs) have been approved by the US Food and Drug Administration (FDA) for the treatment of Merkel cell carcinoma (MCC), cutaneous squamous cell carcinoma (CSCC), and basal cell carcinoma (BCC). Although ICIs have demonstrated activity against NMSCs, the routine clinical use of these agents may be more challenging due to a number of factors including the lack of predictive biomarkers, the need to consider special patient populations, the management of toxicity, and the assessment of atypical responses. With the goal of improving patient care by providing expert guidance to the oncology community, the Society for Immunotherapy of Cancer (SITC) convened a multidisciplinary panel of experts to develop a clinical practice guideline (CPG). The expert panel drew on the published literature as well as their own clinical experience to develop recommendations for healthcare professionals on important aspects of immunotherapeutic treatment for NMSCs, including staging, biomarker testing, patient selection, therapy selection, post-treatment response evaluation and surveillance, and patient quality of life (QOL) considerations, among others. The evidence- and consensus-based recommendations in this CPG are intended to provide guidance to cancer care professionals treating patients with NMSCs.

[1]  M. Suarez‐Almazor,et al.  Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update , 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  J. Schachter,et al.  Health-Related Quality of Life of Patients with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma Treated with Pembrolizumab in KEYNOTE-629 , 2021, Dermatology and Therapy.

[3]  A. Andrikopoulou,et al.  Immune checkpoint inhibitor administration during pregnancy: a case series , 2021, ESMO open.

[4]  A. Hauschild,et al.  Integrated analysis of a phase 2 study of cemiplimab in advanced cutaneous squamous cell carcinoma: extended follow-up of outcomes and quality of life analysis , 2021, Journal for ImmunoTherapy of Cancer.

[5]  S. Billan,et al.  Pembrolizumab for locally advanced and recurrent/metastatic cutaneous squamous cell carcinoma (KEYNOTE-629 Study): an open-label, nonrandomized, multicenter, phase 2 trial. , 2021, Annals of oncology : official journal of the European Society for Medical Oncology.

[6]  Parantu K. Shah,et al.  First-line avelumab in a cohort of 116 patients with metastatic Merkel cell carcinoma (JAVELIN Merkel 200): primary and biomarker analyses of a phase II study , 2021, Journal for ImmunoTherapy of Cancer.

[7]  Jason M. Johnson,et al.  Pilot Phase II Trial of Neoadjuvant Immunotherapy in Locoregionally Advanced, Resectable Cutaneous Squamous Cell Carcinoma of the Head and Neck , 2021, Clinical Cancer Research.

[8]  P. Ascierto,et al.  Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events , 2021, Journal for ImmunoTherapy of Cancer.

[9]  K. Peris,et al.  Health-related quality of life (HRQoL) in patients (pts) with locally advanced basal cell carcinoma (laBCC) treated with cemiplimab: Analysis of a phase II, open-label clinical trial. , 2021 .

[10]  A. Hauschild,et al.  Cemiplimab in locally advanced basal cell carcinoma after hedgehog inhibitor therapy: an open-label, multi-centre, single-arm, phase 2 trial. , 2021, The Lancet. Oncology.

[11]  J. Taube,et al.  Three-year survival, correlates and salvage therapies in patients receiving first-line pembrolizumab for advanced Merkel cell carcinoma , 2021, Journal for ImmunoTherapy of Cancer.

[12]  S. Haferkamp,et al.  Activity of ipilimumab plus nivolumab in avelumab-refractory Merkel cell carcinoma , 2021, Cancer Immunology, Immunotherapy.

[13]  A. Zaniboni,et al.  Association of steroid use with survival in solid tumours. , 2020, European Journal of Cancer.

[14]  M. Weichenthal,et al.  Immune checkpoint inhibition therapy for advanced skin cancer in patients with concomitant hematological malignancy: a retrospective multicenter DeCOG study of 84 patients , 2020, Journal for ImmunoTherapy of Cancer.

[15]  Y. Bang,et al.  Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study. , 2020, The Lancet. Oncology.

[16]  S. D'Angelo,et al.  Health-related quality of life trajectory of treatment-naive patients with Merkel cell carcinoma receiving avelumab , 2020, Future oncology.

[17]  P. Petrow,et al.  Phase II Study of Pembrolizumab As First-Line, Single-Drug Therapy for Patients With Unresectable Cutaneous Squamous Cell Carcinomas. , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  D. Byrd,et al.  Clinical Benefit of Baseline Imaging in Merkel Cell Carcinoma: Analysis of 584 Patients. , 2020, Journal of the American Academy of Dermatology.

[19]  J. Schachter,et al.  Pembrolizumab Monotherapy for Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma: A Single-Arm Phase II Trial (KEYNOTE-629) , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  C. Carrera,et al.  Squamous Cell Carcinoma: An Update on Diagnosis and Treatment , 2020, Dermatology practical & conceptual.

[21]  K. Harrington,et al.  An open-label, single-arm, phase II clinical trial of RP1, an enhanced potency oncolytic herpes virus, combined with nivolumab in four solid tumor types: Initial results from the skin cancer cohorts. , 2020 .

[22]  Parantu K. Shah,et al.  Avelumab in patients with previously treated metastatic Merkel cell carcinoma: long-term data and biomarker analyses from the single-arm phase 2 JAVELIN Merkel 200 trial , 2020, Journal for immunotherapy of cancer.

[23]  S. Arron,et al.  Validation of a 40-Gene Expression Profile Test to Predict Metastatic Risk in Localized High-Risk Cutaneous Squamous Cell Carcinoma. , 2020, Journal of the American Academy of Dermatology.

[24]  J. Taube,et al.  Neoadjuvant Nivolumab for Patients With Resectable Merkel Cell Carcinoma in the CheckMate 358 Trial. , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  P. Googe,et al.  PD‐L1 and LAG‐3 expression in advanced cutaneous squamous cell carcinomas , 2020, Journal of cutaneous pathology.

[26]  Vanessa M. Hubbard-Lucey,et al.  Defining tumor resistance to PD-1 pathway blockade: recommendations from the first meeting of the SITC Immunotherapy Resistance Taskforce , 2020, Journal for ImmunoTherapy of Cancer.

[27]  R. Dummer,et al.  Immunologic Characteristics of Nonmelanoma Skin Cancers: Implications for Immunotherapy. , 2020, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.

[28]  F. Petrelli,et al.  Association of Steroids Use with Survival in Patients Treated with Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis , 2020, Cancers.

[29]  A. Shinagare,et al.  The Safety and Efficacy of Checkpoint Inhibitors in Transplant Recipients: A Case Series and Systematic Review of Literature. , 2020, The oncologist.

[30]  C. Berking,et al.  Cemiplimab in locally advanced cutaneous squamous cell carcinoma: results from an open-label, phase 2, single-arm trial. , 2020, The Lancet. Oncology.

[31]  V. Neel,et al.  Factors Predictive of Recurrence, Metastasis, and Death from Primary Basal Cell Carcinoma 2cm or Larger in Diameter. , 2020, Journal of the American Academy of Dermatology.

[32]  Meiyu Fang,et al.  Angiosarcoma: a review of diagnosis and current treatment. , 2019, American journal of cancer research.

[33]  M. Tetzlaff,et al.  Danger is only skin deep: aggressive epidermal carcinomas. An overview of the diagnosis, demographics, molecular-genetics, staging, prognostic biomarkers, and therapeutic advances in Merkel cell carcinoma , 2019, Modern Pathology.

[34]  V. Sondak,et al.  The Genomic Landscape of Merkel Cell Carcinoma and Clinicogenomic Biomarkers of Response to Immune Checkpoint Inhibitor Therapy , 2019, Clinical Cancer Research.

[35]  J. Castle,et al.  Angiosarcoma patients treated with immune checkpoint inhibitors: a case series of seven patients from a single institution , 2019, Journal of Immunotherapy for Cancer.

[36]  P. Funchain,et al.  Sentinel lymph node biopsy in Merkel cell carcinoma: Predictors of sentinel lymph node positivity and association with overall survival. , 2019, Journal of the American Academy of Dermatology.

[37]  E. Lipson,et al.  Rescue therapy for patients with anti-PD-1-refractory Merkel cell carcinoma: a multicenter, retrospective case series , 2019, Journal of Immunotherapy for Cancer.

[38]  C. Schmults,et al.  Performance of the American Joint Committee on Cancer Staging Manual, 8th Edition vs the Brigham and Women's Hospital Tumor Classification System for Cutaneous Squamous Cell Carcinoma. , 2019, JAMA dermatology.

[39]  Chul Kim,et al.  Safety and Efficacy of Immune Checkpoint Inhibitor Therapy in Patients With HIV Infection and Advanced-Stage Cancer: A Systematic Review. , 2019, JAMA oncology.

[40]  M. Nishino,et al.  Immune Checkpoint Inhibitor Outcomes for Patients With Non-Small-Cell Lung Cancer Receiving Baseline Corticosteroids for Palliative Versus Nonpalliative Indications. , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[41]  Hong Jiang,et al.  Diffuse lichen planus-like keratoses and clinical pseudo-progression associated with avelumab treatment for Merkel cell carcinoma, a case report , 2019, BMC Cancer.

[42]  M. Sznol,et al.  Assessment of the Safety of Pembrolizumab in Patients With HIV and Advanced Cancer-A Phase 1 Study. , 2019, JAMA oncology.

[43]  M. Samimi Immune Checkpoint Inhibitors and Beyond: An Overview of Immune-Based Therapies in Merkel Cell Carcinoma , 2019, American Journal of Clinical Dermatology.

[44]  V. Miller,et al.  Phenotypic and Genomic Determinants of Immunotherapy Response Associated with Squamousness , 2019, Cancer Immunology Research.

[45]  M. Suarez‐Almazor,et al.  Checkpoint inhibitor therapy for cancer in solid organ transplantation recipients: an institutional experience and a systematic review of the literature , 2019, Journal of Immunotherapy for Cancer.

[46]  P. Keegan,et al.  FDA Approval Summary: Pembrolizumab for the Treatment of Microsatellite Instability-High Solid Tumors , 2019, Clinical Cancer Research.

[47]  A. López-Guillermo,et al.  Safety and activity of ibrutinib in combination with nivolumab in patients with relapsed non-Hodgkin lymphoma or chronic lymphocytic leukaemia: a phase 1/2a study. , 2019, The Lancet. Haematology.

[48]  E. Ruiz,et al.  Basal Cell Carcinoma Review. , 2019, Hematology/oncology clinics of North America.

[49]  N. Palanisamy,et al.  Neurofilament is superior to cytokeratin 20 in supporting cutaneous origin for neuroendocrine carcinoma , 2018, Histopathology.

[50]  Carolyn S. Lee,et al.  PD-L1 Expression and Tumor-Infiltrating Lymphocytes in High-Risk and Metastatic Cutaneous Squamous Cell Carcinoma , 2018, Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery.

[51]  J. Taube,et al.  Durable Tumor Regression and Overall Survival in Patients With Advanced Merkel Cell Carcinoma Receiving Pembrolizumab as First-Line Therapy. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[52]  Matthew P. Goetz,et al.  NCCN CLINICAL PRACTICE GUIDELINES IN ONCOLOGY , 2019 .

[53]  G. Linette,et al.  Early objective response to avelumab treatment is associated with improved overall survival in patients with metastatic Merkel cell carcinoma , 2019, Cancer Immunology, Immunotherapy.

[54]  R. Munhoz,et al.  Atypical response with bone pseudoprogression in a patient receiving nivolumab for advanced cutaneous squamous cell carcinoma , 2018, Journal of Immunotherapy for Cancer.

[55]  Qian Chu,et al.  The role of neoantigen in immune checkpoint blockade therapy , 2018, Experimental Hematology & Oncology.

[56]  J. Decaprio,et al.  The biology and treatment of Merkel cell carcinoma: current understanding and research priorities , 2018, Nature Reviews Clinical Oncology.

[57]  Ludmila V. Danilova,et al.  Multidimensional, quantitative assessment of PD-1/PD-L1 expression in patients with Merkel cell carcinoma and association with response to pembrolizumab , 2018, Journal of Immunotherapy for Cancer.

[58]  P. Gibson,et al.  Carboplatin and Pembrolizumab Chemoimmunotherapy Achieves Remission in Recurrent, Metastatic Sebaceous Carcinoma. , 2018, Ophthalmic plastic and reconstructive surgery.

[59]  M. Hara,et al.  Use of Immune Checkpoint Inhibitors in the Treatment of Patients With Cancer and Preexisting Autoimmune Disease , 2018, Annals of Internal Medicine.

[60]  Jianlin Yuan,et al.  Near complete response to Pembrolizumab in microsatellite-stable metastatic sebaceous carcinoma , 2018, Journal of Immunotherapy for Cancer.

[61]  A. Hauschild,et al.  PD‐1 Blockade with Cemiplimab in Advanced Cutaneous Squamous‐Cell Carcinoma , 2018, The New England journal of medicine.

[62]  C. Berking,et al.  Adjuvant ipilimumab compared with observation in completely resected Merkel cell carcinoma (ADMEC): A randomized, multicenter DeCOG/ADO study. , 2018 .

[63]  T. Olencki,et al.  Merkel Cell Carcinoma, Version 1.2018, NCCN Clinical Practice Guidelines in Oncology. , 2018, Journal of the National Comprehensive Cancer Network : JNCCN.

[64]  S. Bhatia,et al.  Advances in Immunotherapy for Metastatic Merkel Cell Carcinoma: A Clinician's Guide. , 2018, Journal of the National Comprehensive Cancer Network : JNCCN.

[65]  J. Kane,et al.  Malignant adnexal tumors of the skin: a single institution experience , 2018, World Journal of Surgical Oncology.

[66]  John A Thompson,et al.  New NCCN Guidelines: Recognition and Management of Immunotherapy-Related Toxicity. , 2018, Journal of the National Comprehensive Cancer Network : JNCCN.

[67]  J. Brahmer,et al.  Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline Summary. , 2018, Journal of oncology practice.

[68]  M. Suarez‐Almazor,et al.  Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[69]  M. Schlichting,et al.  Nonprogression with avelumab treatment associated with gains in quality of life in metastatic Merkel cell carcinoma. , 2018, Future oncology.

[70]  K. Lewis,et al.  Updated efficacy of avelumab in patients with previously treated metastatic Merkel cell carcinoma after ≥1 year of follow-up: JAVELIN Merkel 200, a phase 2 clinical trial , 2018, Journal of Immunotherapy for Cancer.

[71]  L. Dirix,et al.  Emerging trends in the treatment of advanced basal cell carcinoma. , 2017, Cancer treatment reviews.

[72]  A. Stang,et al.  Merkel cell carcinoma: Current US incidence and projected increases based on changing demographics , 2017, Journal of the American Academy of Dermatology.

[73]  T. Chan,et al.  Merkel Cell Carcinoma Patients Presenting Without a Primary Lesion Have Elevated Markers of Immunity, Higher Tumor Mutation Burden, and Improved Survival , 2017, Clinical Cancer Research.

[74]  M. Suarez‐Almazor,et al.  Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group , 2017, Journal of Immunotherapy for Cancer.

[75]  J. Cañueto,et al.  Novel Additions to the AJCC's New Staging Systems for Skin Cancer. , 2017, Actas dermo-sifiliograficas.

[76]  P. Harms Update on Merkel Cell Carcinoma. , 2017, Clinics in laboratory medicine.

[77]  P. Stephens,et al.  Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers , 2017, Molecular Cancer Therapeutics.

[78]  A. Arnold,et al.  Psychosocial distress and desire for support among inpatients with skin cancer , 2017, Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG.

[79]  D. Schadendorf,et al.  Abstract CT074: Non-comparative, open-label, multiple cohort, phase 1/2 study to evaluate nivolumab (NIVO) in patients with virus-associated tumors (CheckMate 358): Efficacy and safety in Merkel cell carcinoma (MCC) , 2017 .

[80]  Deborah A. Bowen,et al.  Pembrolizumab in patients with CLL and Richter transformation or with relapsed CLL. , 2017, Blood.

[81]  P. Greenberg,et al.  Augmentation of adoptive T-cell therapy for Merkel cell carcinoma with avelumab. , 2017 .

[82]  D. Galloway,et al.  Viral oncoprotein antibodies as a marker for recurrence of Merkel cell carcinoma: A prospective validation study , 2017, Cancer.

[83]  J. Taube,et al.  Basal cell carcinoma: PD-L1/PD-1 checkpoint expression and tumor regression after PD-1 blockade , 2017, Journal of Immunotherapy for Cancer.

[84]  D. Schadendorf,et al.  Merkel cell carcinoma: Epidemiology, prognosis, therapy and unmet medical needs. , 2017, European journal of cancer.

[85]  P. Nghiem,et al.  Merkel Cell Carcinoma: An Unusually Immunogenic Cancer Proves Ripe for Immune Therapy. , 2016, Journal of oncology practice.

[86]  P. Googe,et al.  PD‐L1 expression in cutaneous squamous cell carcinoma correlates with risk of metastasis , 2016, Journal of cutaneous pathology.

[87]  P. Nghiem,et al.  Response rates and durability of chemotherapy among 62 patients with metastatic Merkel cell carcinoma , 2016, Cancer medicine.

[88]  V. Sondak,et al.  Adjuvant Radiation Therapy and Chemotherapy in Merkel Cell Carcinoma: Survival Analyses of 6908 Cases From the National Cancer Data Base. , 2016, Journal of the National Cancer Institute.

[89]  A. Sober,et al.  Analysis of Prognostic Factors from 9387 Merkel Cell Carcinoma Cases Forms the Basis for the New 8th Edition AJCC Staging System , 2016, Annals of Surgical Oncology.

[90]  R. Sullivan,et al.  Ipilimumab Therapy in Patients With Advanced Melanoma and Preexisting Autoimmune Disorders. , 2016, JAMA oncology.

[91]  Manish Khanna,et al.  Supportive care needs and distress in patients with non-melanoma skin cancer: Nothing to worry about? , 2016, European journal of oncology nursing : the official journal of European Oncology Nursing Society.

[92]  T. Chan,et al.  Mutational landscape of MCPyV-positive and MCPyV-negative Merkel cell carcinomas with implications for immunotherapy , 2015, Oncotarget.

[93]  A. Bleyer,et al.  The Role of Clinical Trial Participation in Cancer Research: Barriers, Evidence, and Strategies. , 2016, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.

[94]  Gisela Mir Arnau,et al.  UV-Associated Mutations Underlie the Etiology of MCV-Negative Merkel Cell Carcinomas. , 2015, Cancer research.

[95]  S. Feldman,et al.  Incidence Estimate of Nonmelanoma Skin Cancer (Keratinocyte Carcinomas) in the U.S. Population, 2012. , 2015, JAMA dermatology.

[96]  S. Dhanasekaran,et al.  The Distinctive Mutational Spectra of Polyomavirus-Negative Merkel Cell Carcinoma. , 2015, Cancer research.

[97]  M. Burotto,et al.  Pseudoprogression and Immune-Related Response in Solid Tumors. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[98]  P. Sharma,et al.  Immune Checkpoint Targeting in Cancer Therapy: Toward Combination Strategies with Curative Potential , 2015, Cell.

[99]  P. Moore,et al.  Large T and small T antigens of Merkel cell polyomavirus. , 2015, Current opinion in virology.

[100]  Johan Moan,et al.  The relationship between UV exposure and incidence of skin cancer , 2015, Photodermatology, photoimmunology & photomedicine.

[101]  R. Valenti Chemotherapy education for patients with cancer: a literature review. , 2014, Clinical journal of oncology nursing.

[102]  J. McNiff,et al.  p40 is a more specific marker than p63 for cutaneous poorly differentiated squamous cell carcinoma , 2014, Journal of cutaneous pathology.

[103]  Curtis R. Pickering,et al.  Mutational Landscape of Aggressive Cutaneous Squamous Cell Carcinoma , 2014, Clinical Cancer Research.

[104]  Olga K Afanasiev,et al.  Downregulation of MHC-I Expression Is Prevalent but Reversible in Merkel Cell Carcinoma , 2014, Cancer Immunology Research.

[105]  D. Epner,et al.  Managing body image difficulties of adult cancer patients: Lessons from available research , 2014, Cancer.

[106]  A. Qureshi,et al.  Evaluation of American Joint Committee on Cancer, International Union Against Cancer, and Brigham and Women's Hospital tumor staging for cutaneous squamous cell carcinoma. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[107]  Shyam S Jayaraman,et al.  Mutational landscape of basal cell carcinomas by whole-exome sequencing. , 2014, The Journal of investigative dermatology.

[108]  D. Epner,et al.  Managing body image difficulties of adult cancer patients: Lessons from available research , 2014, Cancer.

[109]  Annie Heng,et al.  Real-world impact of education: treating patients with ipilimumab in a community practice setting , 2013, Cancer management and research.

[110]  C. Desmarais,et al.  Regression of Metastatic Merkel Cell Carcinoma Following Transfer of Polyomavirus-Specific T Cells and Therapies Capable of Reinducing HLA Class-I , 2013, Cancer Immunology Research.

[111]  A. Qureshi,et al.  Basal-cell carcinoma incidence and associated risk factors in U.S. women and men. , 2013, American journal of epidemiology.

[112]  Olga K Afanasiev,et al.  Merkel Polyomavirus-Specific T Cells Fluctuate with Merkel Cell Carcinoma Burden and Express Therapeutically Targetable PD-1 and Tim-3 Exhaustion Markers , 2013, Clinical Cancer Research.

[113]  A. Abernethy,et al.  The financial toxicity of cancer treatment: a pilot study assessing out-of-pocket expenses and the insured cancer patient's experience. , 2013, The oncologist.

[114]  W. Al-Refaie,et al.  Does enrollment in cancer trials improve survival? , 2013, Journal of the American College of Surgeons.

[115]  A. Carsin,et al.  Associations between cancer‐related financial stress and strain and psychological well‐being among individuals living with cancer , 2013, Psycho-oncology.

[116]  W. Hwang,et al.  Evaluation of AJCC tumor staging for cutaneous squamous cell carcinoma and a proposed alternative tumor staging system. , 2013, JAMA dermatology.

[117]  G. Edgren,et al.  Risk of skin cancer and other malignancies in kidney, liver, heart and lung transplant recipients 1970 to 2008—A Swedish population‐based study , 2013, International journal of cancer.

[118]  E. M. Warton,et al.  HIV infection status, immunodeficiency, and the incidence of non-melanoma skin cancer. , 2013, Journal of the National Cancer Institute.

[119]  L. Dourmishev,et al.  Clinical variants, stages, and management of basal cell carcinoma , 2013, Indian dermatology online journal.

[120]  J. Taube,et al.  PD-L 1 Expression in the Merkel Cell Carcinoma Microenvironment : Association with In fl ammation , Merkel Cell Polyomavirus , and Overall Survival , 2013 .

[121]  R. D'Agostino,et al.  Itch and pain in nonmelanoma skin cancer: pain as an important feature of cutaneous squamous cell carcinoma. , 2012, Archives of dermatology.

[122]  J. Leonardi-Bee,et al.  A systematic review of worldwide incidence of nonmelanoma skin cancer , 2012, The British journal of dermatology.

[123]  S. Jalkanen,et al.  Tumor Infiltrating Immune Cells and Outcome of Merkel Cell Carcinoma: A Population-Based Study , 2012, Clinical Cancer Research.

[124]  V. Samarasinghe,et al.  Nonmelanoma Skin Cancer , 2012, Journal of cutaneous and aesthetic surgery.

[125]  G. Schackert,et al.  Tumor Evasion from T Cell Surveillance , 2011, Journal of biomedicine & biotechnology.

[126]  S. Fadaei,et al.  Effects of cognitive behavioral counseling on body Image following mastectomy* , 2011, Journal of research in medical sciences : the official journal of Isfahan University of Medical Sciences.

[127]  N. Lee,et al.  Radiation therapy in the management of Merkel cell carcinoma: current perspectives. , 2011, Expert review of dermatology.

[128]  J. Schelter,et al.  Transcriptome-wide studies of merkel cell carcinoma and validation of intratumoral CD8+ lymphocyte invasion as an independent predictor of survival. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[129]  D. Kraus,et al.  Recurrence and Survival in Patients Undergoing Sentinel Lymph Node Biopsy for Merkel Cell Carcinoma: Analysis of 153 Patients from a Single Institution , 2011, Annals of Surgical Oncology.

[130]  R. Phelps,et al.  Histopathological Variants of Cutaneous Squamous Cell Carcinoma: A Review , 2010, Journal of skin cancer.

[131]  S. Greenfield,et al.  Clinical practice guidelines we can trust , 2011 .

[132]  Richa,et al.  Molecular Mechanisms of Ultraviolet Radiation-Induced DNA Damage and Repair , 2010, Journal of nucleic acids.

[133]  D. Galloway,et al.  Antibodies to merkel cell polyomavirus T antigen oncoproteins reflect tumor burden in merkel cell carcinoma patients. , 2010, Cancer research.

[134]  D. Lott,et al.  Aggressive Behavior of Nonmelanotic Skin Cancers in Solid Organ Transplant Recipients , 2010, Transplantation.

[135]  Soumya Krishnamurthy,et al.  Cellular Responses to Cisplatin-Induced DNA Damage , 2010, Journal of nucleic acids.

[136]  C. Quirk,et al.  Sustained clearance of superficial basal cell carcinomas treated with imiquimod cream 5%: results of a prospective 5-year study. , 2010, Cutis.

[137]  V. Preedy,et al.  European Organization for Research and Treatment of Cancer , 2010 .

[138]  L. Schover,et al.  Cancer and sexual problems. , 2010, The journal of sexual medicine.

[139]  H. Joensuu,et al.  Chronic lymphocytic leukaemia patients have a high risk of Merkel-cell polyomavirus DNA-positive Merkel-cell carcinoma , 2009, British Journal of Cancer.

[140]  B. Stahl,et al.  Tetrada of the possible mycophenolate mofetil embryopathy: a review. , 2009, Reproductive toxicology.

[141]  J. F. Baumgratz,et al.  Even low dose of mycophenolate mofetil in a mother recipient of heart transplant can seriously damage the fetus. , 2008, Transplantation.

[142]  P. Moore,et al.  Clonal Integration of a Polyomavirus in Human Merkel Cell Carcinoma , 2008, Science.

[143]  D. Coit,et al.  Merkel cell carcinoma , 2001, Cancer.

[144]  D. Manos,et al.  Body image and self-esteem in women with breast cancer participating in a psychosocial intervention program , 2008 .

[145]  Jean Kanitakis,et al.  Expression of p63 in cutaneous metastases. , 2007, American journal of clinical pathology.

[146]  M. Mazumdar,et al.  Role of radiologic imaging at the time of initial diagnosis of stage T1b‐T3b melanoma , 2007, Cancer.

[147]  M. Falster,et al.  Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a meta-analysis , 2007, The Lancet.

[148]  P. Nghiem,et al.  Merkel cell carcinoma adjuvant therapy: current data support radiation but not chemotherapy. , 2007, Journal of the American Academy of Dermatology.

[149]  A. Vilalta,et al.  Lymphatic mapping and sentinel node biopsy in Merkel's cell carcinoma. , 2007, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[150]  M. Weinstock,et al.  Adjuvant local irradiation for Merkel cell carcinoma. , 2006, Archives of dermatology.

[151]  P. Nghiem,et al.  Sentinel lymph node biopsy for evaluation and treatment of patients with Merkel cell carcinoma: The Dana-Farber experience and meta-analysis of the literature. , 2006, Archives of dermatology.

[152]  K. Camphausen,et al.  Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy , 2006, The Journal of experimental medicine.

[153]  C. Papadimitriou,et al.  Immunohistochemical Distinction Between Merkel Cell Carcinoma and Small Cell Carcinoma of the Lung , 2006, The American Journal of dermatopathology.

[154]  J. M. Martín,et al.  Clinicopathological and immunohistochemical analysis of 20 cases of Merkel cell carcinoma in search of prognostic markers , 2005, Histopathology.

[155]  L. Golitz,et al.  Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: results from two phase III, randomized, vehicle-controlled studies. , 2004, Journal of the American Academy of Dermatology.

[156]  J. Goedert,et al.  Merkel cell carcinoma and HIV infection , 2002, The Lancet.

[157]  C. Balch,et al.  AJCC Cancer Staging Manual. 6th ed , 2002 .

[158]  C. Compton,et al.  AJCC Cancer Staging Manual , 2002, Springer New York.

[159]  B. Armstrong,et al.  The epidemiology of UV induced skin cancer. , 2001, Journal of photochemistry and photobiology. B, Biology.

[160]  S Hansen,et al.  Skin cancer in kidney and heart transplant recipients and different long-term immunosuppressive therapy regimens. , 1999, Journal of the American Academy of Dermatology.

[161]  S. Suster,et al.  Cytokeratin 20 immunoreactivity distinguishes Merkel cell (primary cutaneous neuroendocrine) carcinomas and salivary gland small cell carcinomas from small cell carcinomas of various sites. , 1997, The American journal of surgical pathology.

[162]  M. Melbye,et al.  Evidence of an association between non-Hodgkin's lymphoma and skin cancer , 1995, BMJ.

[163]  M A Weinstock,et al.  Nonmelanoma skin cancer in the United States: incidence. , 1994, Journal of the American Academy of Dermatology.

[164]  R. Manne,et al.  Neurofilament immunoreactivity in Merkel-cell tumors: a differentiating feature from small-cell carcinoma. , 1993, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.

[165]  R. Moll,et al.  Cytokeratin 20 in human carcinomas. A new histodiagnostic marker detected by monoclonal antibodies. , 1992, The American journal of pathology.

[166]  J. Ortonne,et al.  Normal Merkel cells express a synaptophysin-like immunoreactivity. , 1988, Dermatologica.

[167]  H. von Domarus,et al.  Metastatic basal cell carcinoma , 1984 .

[168]  J. Polak,et al.  Immunostaining of neuron‐specific enolase as a diagnostic tool for merkel cell tumors , 1983, Cancer.